Blm10-Based Compounds Add to the Knowledge of How Allosteric Modulators Influence Human 20S Proteasome

Julia Witkowska1, Małgorzata Giżyńska1, Przemysław Karpowicz1

  • 1Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk 80-308, Poland.

ACS Chemical Biology
|February 5, 2025
PubMed

Insights

Researchers developed peptide activators to boost proteasome function, aiding cellular protein degradation and potentially preventing age-related diseases caused by protein aggregation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cellular Biology

Background:

  • Proteasomes are crucial for protein degradation and cellular homeostasis.
  • Proteasome activity declines with age, leading to the accumulation of damaged proteins and potential pathologies like amyloid plaques.
  • Designing proteasome activators is challenging as they bind away from the active site.

Purpose of the Study:

  • To design and develop novel peptidic activators for the 20S proteasome.
  • To investigate the efficacy of these activators in enhancing protein degradation.
  • To understand the binding mechanism of effective proteasome activators.

Main Methods:

  • Peptidic activators were designed based on the Blm10 protein sequence and molecular modeling.
  • The activity of these analogs was tested on human 20S proteasome using fluorogenic substrates and proteins.
  • X-ray crystallography was used to determine the binding mode of the activators.

Main Results:

  • Designed Blm analogs effectively stimulated the human 20S proteasome's degradation activity.
  • The best activators showed efficacy in cell lysates.
  • X-ray crystallography revealed that activators bind to the proteasome surface without causing permanent structural changes near the active sites.

Conclusions:

  • Peptidic activators based on Blm10 can enhance proteasome function.
  • These activators offer a promising strategy for combating pathologies associated with impaired protein degradation.
  • Understanding activator binding sites is key to developing targeted therapeutic interventions.

Related Concept Videos

Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K